Allogeneic Cell Therapy Articles & Analysis: Older
2 articles found
In hematological malignancies, complete response rates to CAR-T cells can exceed 80%. These responses are often durable in nature and have attracted considerable excitement and investment in the development of cell therapies for an expanded range of indications, particularly in solid tumors. ...
We are developing an injectable disc cell therapy (IDCT) that has the potential to disrupt the way chronic back pain is treated. IDCT is an allogeneic, non-surgical cell therapy, meaning it’s an injectable treatment that is produced from donor tissue (as opposed to the patient’s own) and available ...